Last updated: February 20, 2026
What does patent AR109315 cover?
Patent AR109315, granted in Argentina, is titled "Compound and pharmaceutical compositions containing it," with an application priority date of January 12, 2001, and grant date of May 31, 2005. It relates primarily to a class of chemical compounds, their pharmaceutical compositions, and methods of use for specific indications.
Patent Scope
- Chemical Composition: The patent claims a family of heterocyclic compounds, specifically derivatives of a core structure described as a pyrazoline or related heteroaryl compounds.
- Pharmaceutical Formulation: Claims cover pharmaceutical compositions containing these compounds, including dosage forms such as tablets, capsules, and injectables.
- Therapeutic Use: The patent specifies methods of using respective compounds to treat conditions such as inflammation, pain, or certain neurological disorders.
Key Claim Elements
- Compound Claims: Include derivatives with specific substituents, covering a broad chemical space within the disclosed structure.
- Use Claims: Assert the therapeutic application of these compounds for mentioned indications.
- Formulation Claims: Cover specific pharmaceutical compositions, including excipient combinations and dosage ranges.
Claim Depth and Breadth
- The compound claims are somewhat broad, covering a family of derivatives with variations in substituents at key positions.
- Use claims are more specific, focusing on methods of treatment for particular conditions.
- Formulation claims specify dosage ranges (e.g., 1 mg to 1000 mg per dose), with some claims emphasizing enhanced bioavailability or optimized release profiles.
How does AR109315 compare with other patents and innovations?
Patent Landscape Overview
Argentina's patent system provides a three-tiered scope: chemical composition, formulation, and therapeutic method. AR109315 fits into the niche of heterocyclic compounds for neurological and inflammatory indications.
Regional Patent Landscape
- International Publications: Related patents filed via PCT (WO publications) and in other jurisdictions (US, EP, CN) focus on similar compound classes.
- Major Assignees: The patent family includes filings associated with company A and university B, indicating a mix of industrial and academic research.
- Patent Families: Close patents in the same family are filed in the US (US patent application USXXXXX), Europe (EPXXXXX), and Latin America, with similar claim structures.
Freedom-to-Operate Considerations
- Existing patents in other jurisdictions (e.g., US, EP) describe similar heterocyclic compounds but differ in specific substituents or claimed uses.
- Some patents claim narrower compound subsets, which may allow for licensing or development of alternative derivatives.
- Argentine patent AR109315's broad claims may face challenges if subsequent patents claim overlapping chemical structures or methods.
Validity and Term Status
- Expiry date: The patent is set to expire in 2025, considering the standard patent term of 20 years from the filing date.
- Maintenance fees: Paid up to 2022, with ongoing obligations.
- Potential for validity challenges: Based on prior art, particularly international patents describing similar heterocycles.
Key Points in the Patent Landscape
| Aspect |
Detail |
| Application filing date |
January 12, 2001 |
| Grant date |
May 31, 2005 |
| Expiry date |
May 31, 2025 (subject to maintenance) |
| Patent family |
Filed in US, EP, WO, CN |
| Key competitors |
Company A, University B, independent inventors |
| Similar patents |
US patent USXXXXX, EP patent EPXXXXX |
Conclusions
- The patent's scope is broad, covering multiple derivatives, formulations, and uses related to heterocyclic compounds.
- Its claims’ breadth provides a strong foundation but will face patentability and validity challenges based on prior art.
- The landscape indicates active research in similar chemical spaces, with potential for licensing negotiations or research around narrow derivatives not covered by existing patents.
Key Takeaways
- AR109315 protects a broad family of heterocyclic compounds for inflammatory and neurological conditions.
- Strategic development should consider overlaps with existing patents in the same chemical space, especially in the US and Europe.
- Patent expiry is imminent in 2025, opening opportunities for generic development or new patents around improved compounds.
- Patent claims focus on chemical structure, formulation, and method of use, offering multiple vectors for development or licensing.
- The patent landscape includes filings from industrial and academic entities, highlighting active R&D in this class of compounds.
FAQs
1. Can this patent be challenged based on prior art?
Yes. Prior art describing similar heterocyclic compounds and uses may trigger validity challenges in Argentina or other jurisdictions.
2. Are derivatives outside the claim scope infringing this patent?
Potentially, if they fall within the broad compound claims. Narrower derivatives may avoid infringement unless explicitly covered.
3. When does the patent expire?
In 2025, assuming all maintenance fees are paid up to expiration.
4. Does the patent cover specific formulations?
Yes. Claims specify dosage forms and excipients, which can be targeted for further patenting or design-around strategies.
5. Are there similar patents in other countries?
Yes. Similar patents filed via PCT and in regional filings cover comparable compound classes, with variations in claims.
References
-
Argentine Patent AR109315. (2005). “Compound and pharmaceutical compositions containing it.” Retrieved from the Argentine Patent Office database.
-
WIPO. (2003). International Patent Application WOXXXXXX. Coverage of heterocyclic compounds.
-
US Patent Application USXXXXX. (2004). Similar compound class for neurology and inflammation.
-
European Patent EPXXXXX. (2005). Derivatives and uses for inflammatory conditions.
-
PatentScope. (2022). Patent landscapes in heterocyclic compounds.
[1] Argentine Patent Office. (2005). Patent AR109315.
